|
Hologic ، Inc. (HOLX) DCF تقييم
US | Healthcare | Medical - Instruments & Supplies | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Hologic, Inc. (HOLX) Bundle
تُمكّنك حاسبة DCF الخاصة بـ Hologic ، Inc. (HOLX) DCF من تقييم تقييم Hologic باستخدام البيانات المالية في العالم الحقيقي مع توفير مرونة كاملة لتعديل جميع المعلمات الأساسية للتوقعات المحسنة.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,776.4 | 5,632.3 | 4,862.8 | 4,030.4 | 4,030.3 | 4,215.3 | 4,408.8 | 4,611.2 | 4,822.9 | 5,044.3 |
| Revenue Growth, % | 0 | 49.14 | -13.66 | -17.12 | -0.00248114 | 4.59 | 4.59 | 4.59 | 4.59 | 4.59 |
| EBITDA | 1,496.7 | 2,861.6 | 2,113.4 | 1,110.6 | 1,296.2 | 1,632.3 | 1,707.2 | 1,785.6 | 1,867.6 | 1,953.3 |
| EBITDA, % | 39.63 | 50.81 | 43.46 | 27.56 | 32.16 | 38.72 | 38.72 | 38.72 | 38.72 | 38.72 |
| Depreciation | 376.0 | 406.9 | 430.1 | 323.4 | 309.0 | 351.7 | 367.8 | 384.7 | 402.4 | 420.9 |
| Depreciation, % | 9.96 | 7.22 | 8.84 | 8.02 | 7.67 | 8.34 | 8.34 | 8.34 | 8.34 | 8.34 |
| EBIT | 1,120.7 | 2,454.7 | 1,683.3 | 787.2 | 987.2 | 1,280.6 | 1,339.4 | 1,400.9 | 1,465.2 | 1,532.5 |
| EBIT, % | 29.68 | 43.58 | 34.62 | 19.53 | 24.49 | 30.38 | 30.38 | 30.38 | 30.38 | 30.38 |
| Total Cash | 701.0 | 1,170.3 | 2,339.5 | 2,722.5 | 2,333.6 | 1,794.9 | 1,877.3 | 1,963.5 | 2,053.6 | 2,147.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,028.9 | 942.7 | 617.6 | 625.6 | 600.4 | 734.3 | 768.0 | 803.3 | 840.2 | 878.7 |
| Account Receivables, % | 27.25 | 16.74 | 12.7 | 15.52 | 14.9 | 17.42 | 17.42 | 17.42 | 17.42 | 17.42 |
| Inventories | 395.1 | 501.2 | 623.7 | 617.6 | 679.8 | 542.7 | 567.7 | 593.7 | 621.0 | 649.5 |
| Inventories, % | 10.46 | 8.9 | 12.83 | 15.32 | 16.87 | 12.88 | 12.88 | 12.88 | 12.88 | 12.88 |
| Accounts Payable | 178.8 | 215.9 | 197.7 | 175.2 | 203.8 | 185.8 | 194.3 | 203.2 | 212.6 | 222.3 |
| Accounts Payable, % | 4.73 | 3.83 | 4.07 | 4.35 | 5.06 | 4.41 | 4.41 | 4.41 | 4.41 | 4.41 |
| Capital Expenditure | -156.4 | -162.7 | -127.2 | -150.2 | -140.2 | -142.1 | -148.6 | -155.4 | -162.5 | -170.0 |
| Capital Expenditure, % | -4.14 | -2.89 | -2.62 | -3.73 | -3.48 | -3.37 | -3.37 | -3.37 | -3.37 | -3.37 |
| Tax Rate, % | 8.74 | 8.74 | 8.74 | 8.74 | 8.74 | 8.74 | 8.74 | 8.74 | 8.74 | 8.74 |
| EBITAT | 1,247.4 | 1,945.7 | 1,380.0 | 530.9 | 900.9 | 1,075.6 | 1,125.0 | 1,176.6 | 1,230.6 | 1,287.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 221.8 | 2,207.1 | 1,867.3 | 679.7 | 1,061.3 | 1,270.3 | 1,294.1 | 1,353.5 | 1,415.7 | 1,480.7 |
| WACC, % | 8.04 | 7.9 | 7.91 | 7.81 | 7.98 | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 5,419.1 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 1,525 | |||||||||
| Terminal Value | 30,948 | |||||||||
| Present Terminal Value | 21,133 | |||||||||
| Enterprise Value | 26,552 | |||||||||
| Net Debt | 498 | |||||||||
| Equity Value | 26,054 | |||||||||
| Diluted Shares Outstanding, MM | 238 | |||||||||
| Equity Value Per Share | 109.68 |
What You Will Get
- Real HOLX Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Explore various scenarios to assess Hologic’s future performance.
- User-Friendly Design: Designed for professionals but easy to navigate for beginners.
Key Features
- Comprehensive Financial Data: Hologic, Inc.'s (HOLX) historical financial statements and pre-filled projections.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Valuation: Observe Hologic, Inc.'s (HOLX) intrinsic value update instantly.
- Intuitive Visualizations: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A professional-grade tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Hologic, Inc. (HOLX) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Hologic, Inc. (HOLX)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Hologic, Inc. (HOLX)?
- Accurate Data: Up-to-date Hologic financials provide dependable valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Built-in calculations save you the effort of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the healthcare sector.
- User-Friendly: Simple design and clear instructions make it accessible for all users.
Who Should Use Hologic, Inc. (HOLX)?
- Healthcare Investors: Make informed investment choices with a comprehensive analysis of Hologic's market performance.
- Medical Analysts: Streamline your research with a detailed financial model tailored for Hologic, Inc. (HOLX).
- Consultants: Efficiently modify the provided data for client discussions or strategic presentations regarding Hologic's offerings.
- Health Sector Enthusiasts: Enhance your knowledge of the medical technology industry through in-depth case studies of Hologic, Inc. (HOLX).
- Educators and Students: Leverage it as a valuable resource in courses focused on healthcare finance and investment strategies.
What the Template Contains
- Historical Data: Includes Hologic, Inc.'s (HOLX) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Hologic, Inc.'s (HOLX) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Hologic, Inc.'s (HOLX) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.